Schott Pharma upgraded to Outperform from Sector Perform at RBC Capital

RBC Capital upgraded Schott Pharma to Outperform from Sector Perform with a price target of EUR 21, up from EUR 18. Preliminary Q3 figures show CER revenue growth of about 8% and an EBITDA margin of about 27%, notes the analyst, who also points out that the pre-announcement came with FY26 guidance raised to 5-6% CER revenue growth from 2-5% and 27-28% EBITDA margin guidance.